Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC May 13, 2025
Enhertu followed by THP before surgery showed statistically significant pCR improvement high-risk HER2-positive early-stage breast cancer patients in DESTINY-Breast11 Ph 3 trial May 13, 2025
IND Clearance obtained for Ph 1b/2 Trial of LP-184 + ICIs in NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression May 13, 2025
First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer May 13, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer May 13, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer patients May 13, 2025
Cellipont Bioservices and Optieum Biotechnologies Partner to Advance cGMP Manufacturing of CAR-T Therapy for Glioblastoma May 13, 2025
First patient dosed in the randomized Ph 1/2 study of roginolisib in combination with dostarlimab with or without docetaxel, in advanced NSCLC patients May 13, 2025
Next phase of clinical development for cemsidomide to be enabled with new studies expected to initiate in early 2026 May 13, 2025
Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
Imfinzi regimen demonstrated statistically significant DFS improvement in high-risk NMIBC in POTOMAC Ph 3 trial May 13, 2025
Preliminary Clinical Data for CT0596 Announced, Demonstrating Favorable Safety and Efficacy May 13, 2025
Elironrasib monotherapy demonstrated acceptable tolerability and encouraging initial antitumor activity in previously treated G12C NSCLC patients May 13, 2025
FDA Advisory Committee Announced for UGN-102 for Recurrent Low-Grade Intermediate-Risk NMIBC May 13, 2025
FDA lifts the clinical hold on IND applications for the EBVALLO™ (tabelecleucel) program May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
US FDA grants Orphan Drug Designation to THE001 for the treatment of soft tissue sarcomas (STS) May 13, 2025
